HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $453,168 | -0.7% | 11,863 | -6.2% | 0.00% | – |
Q2 2023 | $456,177 | -5.3% | 12,647 | +0.3% | 0.00% | – |
Q1 2023 | $481,690 | -42.4% | 12,613 | -14.1% | 0.00% | -100.0% |
Q4 2022 | $835,919 | +18.6% | 14,691 | -17.5% | 0.00% | 0.0% |
Q3 2022 | $705,000 | -6.4% | 17,804 | +3.9% | 0.00% | 0.0% |
Q2 2022 | $753,000 | +12.2% | 17,131 | +1.8% | 0.00% | 0.0% |
Q1 2022 | $671,000 | +30.8% | 16,826 | +31.9% | 0.00% | – |
Q4 2021 | $513,000 | -42.6% | 12,760 | -42.0% | 0.00% | -100.0% |
Q3 2021 | $894,000 | +13.3% | 21,989 | +26.5% | 0.00% | 0.0% |
Q2 2021 | $789,000 | +3.4% | 17,380 | -5.1% | 0.00% | 0.0% |
Q1 2021 | $763,000 | +14.4% | 18,305 | +17.3% | 0.00% | 0.0% |
Q4 2020 | $667,000 | -34.5% | 15,611 | -59.7% | 0.00% | 0.0% |
Q3 2020 | $1,019,000 | -1.6% | 38,768 | +0.3% | 0.00% | 0.0% |
Q2 2020 | $1,036,000 | +28.9% | 38,659 | -13.5% | 0.00% | 0.0% |
Q1 2020 | $804,000 | +17.2% | 44,687 | +15.6% | 0.00% | 0.0% |
Q4 2019 | $686,000 | +13.6% | 38,662 | -0.8% | 0.00% | 0.0% |
Q3 2019 | $604,000 | -9.6% | 38,990 | +0.2% | 0.00% | 0.0% |
Q2 2019 | $668,000 | +7.1% | 38,903 | +0.5% | 0.00% | 0.0% |
Q1 2019 | $624,000 | +10.4% | 38,703 | +0.0% | 0.00% | 0.0% |
Q4 2018 | $565,000 | -19.5% | 38,694 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $702,000 | +7.7% | 38,694 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $652,000 | -14.1% | 38,694 | -0.0% | 0.00% | 0.0% |
Q1 2018 | $759,000 | -5.5% | 38,700 | -2.5% | 0.00% | 0.0% |
Q4 2017 | $803,000 | +4623.5% | 39,694 | +3869.4% | 0.00% | – |
Q3 2017 | $17,000 | +30.8% | 1,000 | 0.0% | 0.00% | – |
Q2 2017 | $13,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
Q1 2017 | $13,000 | +160.0% | 1,000 | +82.1% | 0.00% | – |
Q2 2016 | $5,000 | 0.0% | 549 | -3.7% | 0.00% | – |
Q1 2016 | $5,000 | -99.3% | 570 | -98.6% | 0.00% | -100.0% |
Q4 2015 | $683,000 | +53.5% | 39,459 | +19.0% | 0.00% | 0.0% |
Q3 2015 | $445,000 | -56.8% | 33,168 | -27.3% | 0.00% | 0.0% |
Q2 2015 | $1,030,000 | +74.6% | 45,594 | +10.1% | 0.00% | 0.0% |
Q1 2015 | $590,000 | +54.5% | 41,399 | +4.5% | 0.00% | – |
Q4 2014 | $382,000 | +11.0% | 39,598 | +5.0% | 0.00% | – |
Q3 2014 | $344,000 | -47.2% | 37,724 | -42.9% | 0.00% | -100.0% |
Q2 2014 | $652,000 | +16200.0% | 66,022 | +22666.2% | 0.00% | – |
Q1 2014 | $4,000 | – | 290 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |